Molecular genetics of meningiomas: From basic research to potential clinical applications

Neurosurgery

Volumn 60, Issue 5, 2007, Pages 787-798

  Simon, Matthias ^a,c   Boström, Jan P ^a   Hartmann, Christian ^b  

^a UNIVERSITY OF BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Meningioma; Meningioma progression; Meningioma therapy; Molecular genetics; NF2

Indexed keywords

ERLOTINIB; GEFITINIB; GROWTH FACTOR; HORMONE RECEPTOR; IMATINIB; MERLIN; MEVINOLIN; MIFEPRISTONE; PEGVISOMANT; TAMOXIFEN;

CELL CYCLE; CHROMOSOME 10Q; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 9P; CLINICAL TRIAL; DISEASE COURSE; GENE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; INCIDENCE; MEDICAL RESEARCH; MEMBRANE POTENTIAL; MENINGIOMA; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NEUROFIBROMATOSIS TYPE 2 GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TELOMERE;

ANIMALS; BIOMEDICAL RESEARCH; GENE THERAPY; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MOLECULAR BIOLOGY;

EID: 34247602534     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000255421.78431.AE     Document Type: Review

References (120)

1. Albertson DG, Collins C, McCormick F, Gray JW: Chromosome aberrations in solid tumors. Nat Genet 34:369-376, 2003.
2. Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ: Radiation-induced meningiomas: Clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg 100:1002-1013, 2004.
3. Amatya VJ, Takeshima Y, Inai K: Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705-710, 2004.
4. Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H: Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir (Wien) 140:377-386, 1998.
5. Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer A, Zhuang Z, Venzon DJ, Gibril F, Jensen RT: Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 10:869-880, 2004.
6. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M: Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58:2298-2303, 1998.
7. Boström J, Mühlbauer A, Reifenberger G: Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol (Berl) 94:479-485, 1997.
8. Boström J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58:29-33, 1998.
9. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G: Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669, 2001.
10. Büschges R, Boström J, Wolter M, Blaschke B, Weber RG, Lichter P, Collins VP, Reifenberger G: Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer 92:551-554, 2001.
11. Büschges R, Ichimura K, Weber RG, Reifenberger G, Collins VP: Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 12:145-153, 2002.
12. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature 392:300-303, 1998.
13. Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, Guha A: Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87:315-323, 1997.
14. Chen HJ, Liang CL, Lu K, Lin JW, Cho CL: Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 89:2092-2098, 2000.
15. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, Wolkenstein P: Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122:473-481, 1999.
16. Dezamis E, Sanson M: The molecular genetics of meningiomas and genotypic/phenotypic correlations [in French]. Rev Neurol (Paris) 159:727-738, 2003.
17. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B: Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242:683-688, 1995.
18. Dirven CM, Grill J, Lamfers ML, Van der Valk P, Leonhart AM, Van Beusechem VW, Haisma HJ, Pinedo HM, Curiel DT, Vandertop WP, Gerritsen WR: Gene therapy for meningioma: Improved gene delivery with targeted adenoviruses. J Neurosurg 97:441-449, 2002.
19. Donnell MS, Meyer GA, Donegan WL: Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 50:499-502, 1979.
20. Drummond KJ, Zhu JJ, Black PM: Meningiomas: Updating basic science, management, and outcome. Neurologist 10:113-130, 2004.
21. Gallagher PG: Hereditary elliptocytosis: Spectrin and protein 4.1R. Semin Hematol 41:142-164, 2004.
22. Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL, Gillespie GY: Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40:1269-1277, 1997.
23. Goldstein RA, Jorden MA, Harsh GR 4th: Meningiomas: Natural history, diagnosis, and imaging, in Black PM, Loeffler JS (eds): Cancer of the Nervous System. Philadelphia, Lippincott Williams & Wilkins, 2005, pp 279-314.
24. Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine 66:98-113, 1987.
25. Goto M, Miller RW, Ishikawa Y, Sugano H: Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5:239-246, 1996.
26. Greider CW: Telomerase activation. One step on the road to cancer? Trends Genet 15:109-112, 1999.
27. Grunberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, Russel C, Kabbinavar F, Barger GR, Stelzer KJ: Phase III double-blind randomized placebo controlled study of mifepristone (RU486) for the treatment of unresectable meningioma. ACSO Proc 20:56a, 2001.
28. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF: Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9:1495-1500, 2000.
29. Hartmann C, Sieberns J, Gehlhaar C, Simon M, Paulus W, von Deimling A: NF2 mutations in secretory and other rare variants of meningiomas. Brain Pathol 16:15-19, 2006.
30. Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M: Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer 10:483-488, 2003.
31. Henn W, Cremerius U, Heide G, Lippitz B, Schroder JM, Gilsbach JM, Bull U, Zang KD: Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 79:144-148, 1995.
32. Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J, Maruta H: A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 10:20-26, 2004.
33. Jensen RL, Leppla D, Rokosz N, Wurster RD: Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery 42:130-136, 1998.
34. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, von Deimling A: Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 94:218-221, 2001.
35. Johnson MD, Woodard A, Kim P, Frexes-Steed M: Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 94:293-300, 2001.
36. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS: Lovastatin is a potent inhibitor of meningioma cell proliferation: Evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56:133-142, 2002.
37. Joseph JT, Lisle DK, Jacoby LB, Paulus W, Barone R, Cohen ML, Roggendorf WH, Bruner JM, Gusella JF, Louis DN: NF2 gene analysis distinguishes hemangiopericytoma from meningioma. Am J Pathol 147:1450-1455, 1995.
38. Kalala JP, Maes L, Vandenbroecke C, de Ridder L: The hTERT protein as a marker for malignancy in meningiomas. Oncol Rep 13:273-277, 2005.
39. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M: Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065, 2002.
40. Kanno H, Yamamoto I, Yoshida M, Kitamura H: Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease. Neurology 60:1197-1199, 2003.
41. Kaufmann D, Leistner W, Kruse P, Kenner O, Hoffmeyer S, Hein C, Vogel W, Messiaen L, Bartelt B: Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2. Cancer Res 62:1503-1509, 2002.
42. Kedra D, Peyrard M, Fransson I, Collins JE, Dunham I, Roe BA, Dumanski JP: Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11. Hum Mol Genet 5:625-631, 1996.
43. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, Nishi T, Yamashima T, Moritake K, Saya H, Nakao M: The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 4:915-922, 1998.
44. Kitange G, Tsunoda K, Anda T, Nakamura S, Yasunaga A, Naito S, Shibata S: Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer 89:2292-2300, 2000.
45. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E al: NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367-372, 2001.
46. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M: Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103-110, 1999.
47. Lamszus K: Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275-286, 2004.
48. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Wright WE, Shay JW: Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28:416-420, 1997.
49. Larson JJ, Tew JM Jr, Simon M, Menon AG: Evidence for clonal spread in the development of multiple meningiomas. J Neurosurg 83:705-709, 1995.
50. Leblanc R: Familial adenomatous polyposis and benign intracranial tumors: A new variant of Gardner's syndrome. Can J Neurol Sci 27:341-346, 2000.
51. Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC, Bootsma D, de Jong PJ, Menon AG, Kley NA: Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 10:1521-1528, 1995.
52. Leuraud P, Dezamis E, Aguirre-Cruz L, Taillibert S, Lejeune J, Robin E, Mokhtari K, Boch AL, Cornu P, Delattre JY, Sanson M: Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 100:303-309, 2004.
53. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416-425, 2005.
54. Lomas J, Aminoso C, Gonzalez-Gomez P, Eva Alonso M, Arjona D, Lopez-Marin I, de Campos JM, Isla A, Vaquero J, Gutierrez M, Rey JA: Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148-151, 2004.
55. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J, Rey JA: Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42:314-319, 2005.
56. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ: Meningiomas, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon, IARC Press, 2000, pp 176-184.
57. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121-7126, 2005.
58. Lyons CJ, Wilson CB, Horton JC: Association between meningioma and Cowden's disease. Neurology 43:1436-1437, 1993.
59. Magrassi L, De-Fraja C, Conti L, Butti G, Infuso L, Govoni S, Cattaneo E: Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg 91:440-446, 1999.
60. Maillo A, Orfao A, Sayagues JM, Diaz P, Gomez-Moreta JA, Caballero M, Santamarta D, Santos-Briz A, Morales F, Tabernero MD: New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 21:3285-3295, 2003.
61. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, Rey JA: Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med 16:771-774, 2005.
62. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074-4082, 2005.
63. McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM, Fuller GN: Intracranial injection of human meningioma cells in athymic mice: An orthotopic model for meningioma growth. J Neurosurg 92:306-314, 2000.
64. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94:487-492, 2001.
65. Meewes C, Bohuslavizki KH, Krisch B, Held-Feindt J, Henze E, Clausen M: Molecular biologic and scintigraphic analyses of somatostatin receptornegative meningiomas. J Nucl Med 42:1338-1345, 2001.
66. Mendiola M, Bello MJ, Alonso J, Leone PE, Vaquero J, Sarasa JL, Kusak ME, De Campos JM, Pestana A, Rey JA: Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32. Mol Carcinog 24:300-304, 1999.
67. Mihaila D, Jankowski M, Gutierrez JA, Rosenblum ML, Newsham IF, Bogler O, Rempel SA; NABTT CNS Consortium: Meningiomas: Loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 9:4443-4451, 2003.
68. Miller RW, Rubinstein JH: Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 56:112-115, 1995.
69. Müller P, Henn W, Niedermayer I, Ketter R, Feiden W, Steudel WI, Zang KD, Steilen-Gimbel H: Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 5:3569-3577, 1999.
70. Nigg EA: Centrosome aberrations: Cause or consequence of cancer progression? Nat Rev Cancer 2:815-825, 2002.
71. Nordqvist AC, Peyrard M, Pettersson H, Mathiesen T, Collins VP, Dumanski JP, Schalling M: A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 57:2611-2614, 1997.
72. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M: Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135-139, 2005.
73. Ono Y, Ueki K, Joseph JT, Louis DN: Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol (Berl) 91:221-225, 1996.
74. Ozaki S, Nishizaki T, Ito H, Sasaki K: Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol 41:167-174, 1999.
75. Pagotto U, Arzberger T, Hopfner U, Sauer J, Renner U, Newton CJ, Lange M, Uhl E, Weindl A, Stalla GK: Expression and localization of endothelin-1 and endothelin receptors in human meningiomas: Evidence for a role in tumoral growth. J Clin Invest 96:2017-2025, 1995.
76. Park YS, Lee JH, Harwalkar JA, Bondar J, Safayhi H, Golubic M: Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol 507:387-393, 2002.
77. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH: Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872-879, 2000.
78. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183-190, 2002.
79. Perry A, Gutmann DH, Reifenberger G: Molecular pathogenesis of meningiomas. J Neurooncol 70:183-202, 2004.
80. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, Lenartz D, Marsh DJ, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 24:3-8, 1998.
81. Peyrard M, Pan HQ, Kedra D, Fransson I, Swahn S, Hartman K, Clifton SW, Roe BA, Dumanski JP: Structure of the promoter and genomic organization of the human beta-adaptin gene (BAM22) from chromosome 22q12. Genomics 36:112-117, 1996.
82. Piaskowski S, Rieske P, Szybka M, Wozniak K, Bednarek A, Pluciennik E, Jaskolski D, Sikorska B, Liberski PP: GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 162:63-67, 2005.
83. Puri S, Joshi BH, Sarkar C, Mahapatra AK, Hussain E, Sinha S: Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer 103:2132-2142, 2005.
84. Rajcan-Separovic E, Maguire J, Loukianova T, Nisha M, Kalousek D: Loss of 1p and 7p in radiation-induced meningiomas identified by comparative genomic hybridization. Cancer Genet Cytogenet 144:6-11, 2003.
85. Rienstein S, Loven D, Israeli O, Ram Z, Rappaport ZH, Barkai G, Goldman B, Aviram-Goldring A, Friedman E: Comparative genomic hybridization analysis of radiation-associated and sporadic meningiomas. Cancer Genet Cytogenet 131:135-140, 2001.
86. Rieske P, Zakrzewska M, Biernat W, Bartkowiak J, Zimmermann A, Liberski PP: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol 71:27-30, 2005.
87. Rohringer M, Sutherland GR, Louw DF, Sima AA: Incidence and clinicopathological features of meningioma. J Neurosurg 71:665-672, 1989.
88. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP, Rouleau GA: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180-184, 1994.
89. Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, Goldman B, Friedman E: Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev 14:969-976, 2005.
90. Sanson M, Cornu P: Biology of meningiomas. Acta Neurochir (Wien) 142:493-505, 2000.
91. Santarius T, Kirsch M, Nikas DC, Imitola J, Black PM: Molecular analysis of alterations of the p18INK4c gene in human meningiomas. Neuropathol Appl Neurobiol 26:67-75, 2000.
92. Schmitz U, Müller W, Weber M, Sevenet N, Delattre O, von Deimling A: INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84:199-201, 2001.
93. Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H: Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 25:772-780, 1994.
94. Shino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T: Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J Neurosurg 91:928-934, 1999.
95. Shoshan Y, Chernova O, Juen SS, Somerville RP, Israel Z, Barnett GH, Cowell JK: Radiation-induced meningioma: A distinct molecular genetic pattern? J Neuropathol Exp Neurol 59:614-620, 2000.
96. Shu J, Lee JH, Harwalkar JA, Oh-Siskovic S, Stacey DW, Golubic M: Adenovirus-mediated gene transfer of dominant negative Ha-Ras inhibits proliferation of primary meningioma cells. Neurosurgery 44:579-588, 1999.
97. Siddique K, Yanamandra N, Gujrati M, Dinh D, Rao JS, Olivero W: Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int J Oncol 22:289-294, 2003.
98. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM Jr, Menon AG: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression. Cancer Res 55:4696-4701, 1995.
99. Simon M, Kokkino AJ, Warnick RE, Tew JM Jr, von Deimling A, Menon AG: Role of genomic instability in meningioma progression. Genes Chromosomes Cancer 16:265-269, 1996.
100. Simon M, Park TW, Leuenroth S, Hans VH, Löning T, Schramm J: Telomerase activity and expression of the telomerase catalytic subunit hTERT in meningioma progression. J Neurosurg 92:832-840, 2000.
101. Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Löning T, Schramm J: Alterations of INK4a/INK4b gene expression and telomerase activation in meningioma progression. J Neurooncol 55:149-158, 2001.
102. Simon M, Boström J, Koch P, Schramm J: Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: Impact of changes of the WHO classification. J Neurol Neurosurg Psychiatr 77:767-773, 2006.
103. Smidt M, Kirsch I, Ratner L: Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. J Clin Invest 86:1151-1157, 1990.
104. Staal FJ, van der Luijt RB, Baert MR, van Drunen J, van Bakel H, Peters E, de Valk I, van Amstel HK, Taphoorn MJ, Jansen GH, van Veelen CW, Burgering B, Staal GE: A novel germline mutation of PTEN associated with brain tumours of multiple lineages. Br J Cancer 86:1586-1591, 2002.
105. Stangl AP, Wellenreuther R, Lenartz D, Kraus JA, Menon AG, Schramm J, Wiestler OD, von Deimling A: Clonality of multiple meningiomas. J Neurosurg 86:853-858, 1997.
106. Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H: Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 84:852-859, 1996.
107. Tse JY, Ng HK, Lo KW, Chong EY, Lam PY, Ng EK, Poon WS, Huang DP: Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. Hum Pathol 29:1200-1207, 1998.
108. van Furth WR, Laughlin S, Taylor MD, Salhia B, Mainprize T, Henkelman M, Cusimano MD, Ackerley C, Rutka JT: Imaging of murine brain tumors using a 1.5 Tesla clinical MRI system. Can J Neurol Sci 30:326-332, 2003.
109. van Tilborg AA, Morolli B, Giphart-Gassler M, de Vries A, van Geenen DA, Lurkin I, Kros JM, Zwarthoff EC: Lack of genetic and epigenetic changes in meningiomas without NF2 loss. J Pathol 208:564-573, 2006.
110. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopman J, Maintz D, Steinbeck S, Wick W, Platten M, Muller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, MOllenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K: Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544-558, 2000.
111. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, Nister M: Detection of TP53 gene mutation in human meningiomas: A study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 64:223-228, 1995.
112. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94:14719-14724, 1997.
113. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A: Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827-832, 1995.
114. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D: The accuracy of meningioma grading: A 10-year retrospective audit. Neuropathol Appl Neurobiol 31:141-149, 2005.
115. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114:249-256, 2005.
116. Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, Menon AG, Warren RS, Chen LC, Scott MP, Epstein EH Jr: Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57:2369-2372, 1997.
117. Yi C, McCarty JH, Troutman SA, Eckman MS, Bronson RT, Kissil JL: Loss of the putative tumor suppressor band 4.1B/Dal1 gene is dispensable for normal development and does not predispose to cancer. Mol Cell Biol 25:10052-10059, 2005.
118. Zang KD: Meningioma: A cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 93:207-220, 2001.
119. Zattara-Cannoni H, Roll P, Figarella-Branger D, Lena G, Dufour H, Grisoli F, Vagner-Capodano AM: Cytogenetic study of six cases of radiation-induced meningiomas. Cancer Genet Cytogenet 126:81-84, 2001.
120. Zucman-Rossi J, Legoix P, Thomas G: Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region. Genomics 38:247-254, 1996.